Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Related Citations for PubMed (Select 15246194)

1.

Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.

Kommareddy A, Coplin MA, Gao F, Behnken D, Romvari E, Read W, Govindan R.

Lung Cancer. 2004 Aug;45(2):221-5.

PMID:
15246194
2.

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.

Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP.

Ann Oncol. 2005 May;16(5):780-5. Epub 2005 Feb 22.

3.

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R.

Oncologist. 2003;8(4):303-6.

4.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):777-84.

6.

A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.

Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y; Lung Oncology Group in Kyushu, Japan.

J Thorac Oncol. 2008 Oct;3(10):1166-71. doi: 10.1097/JTO.0b013e318186a88d.

PMID:
18827614
7.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):785-94.

8.

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.

Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M, Jones SF, Dickson NR, Scullin DC, Bradof JE, Rubinsak JR, Brierre JE, Greco FA.

Clin Lung Cancer. 2005 Sep;7(2):127-32.

PMID:
16179100
9.
10.

Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.

Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP, Yang PC, Yang CH.

J Thorac Oncol. 2006 Jul;1(6):520-5.

PMID:
17409911
11.

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L.

J Clin Oncol. 2003 Jul 15;21(14):2658-63.

PMID:
12860941
12.

Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.

Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J.

J Thorac Oncol. 2006 Jul;1(6):545-50.

PMID:
17409915
13.

[Gefitinib in the treatment of advanced non-small cell lung cancer].

Yang L, Liu XY, Fang J, An TT, Wu MN.

Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):474-7. Chinese.

PMID:
17152500
14.

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.

Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Manegold C.

Clin Lung Cancer. 2006 May;7(6):406-11.

PMID:
16800967
16.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX.

J Exp Clin Cancer Res. 2010 Sep 15;29:126. doi: 10.1186/1756-9966-29-126.

17.

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J.

J Clin Oncol. 2007 Apr 20;25(12):1545-52.

18.

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.

Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T, Hirata K.

J Thorac Oncol. 2009 Mar;4(3):371-5. doi: 10.1097/JTO.0b013e31819846e4.

PMID:
19155998
19.

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.

Deng J, Fang WJ, Zhang XC, Wu DP, Fang HM, Chen J, Qian J, Mou HB, Chu BB, Xu N, Teng LS.

Med Oncol. 2012 Jun;29(2):595-9. doi: 10.1007/s12032-011-9891-2. Epub 2011 Mar 12.

PMID:
21399997
20.

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T.

Lung Cancer. 2011 Nov;74(2):268-73. doi: 10.1016/j.lungcan.2011.03.010. Epub 2011 May 6.

PMID:
21529987
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk